GTBP
GT Biopharma, Inc. (GTBP) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
GTBP’s disclosed R&D intensity is not visible in the provided metrics, limiting evidence of peer-leading environmental process efficiency versus better-disclosed biotech peers.
The absence of reported environmental operating metrics suggests limited transparency, which weakens comparability against peers that disclose energy, emissions, and waste management more fully.
As a clinical-stage biotechnology company, GTBP’s direct environmental footprint is typically lighter than manufacturing-heavy peers, but no provided data confirms superior resource efficiency.
No material environmental controversies or regulatory breaches are provided, so GTBP appears broadly in line with peers on environmental risk management rather than advantaged.
Social
GTBP’s provided metrics do not show workforce, safety, or clinical-trial conduct indicators, reducing visibility into social performance versus more transparent peers.
Low stock-based compensation to revenue is not a social metric, but the lack of broader employee and patient-safety disclosure limits evidence of stronger stakeholder management.
Biotechnology peers with robust trial governance and patient-safety reporting generally present clearer social positioning, while GTBP’s available data remains too sparse to show outperformance.
No social controversies are provided, so GTBP appears neutral on social risk, but the disclosure gap prevents a stronger relative ESG assessment.
Governance
GTBP’s net debt to EBITDA of 0.24 suggests limited leverage-related governance pressure, which is modestly better than more indebted peers.
Zero reported stock-based compensation to revenue indicates no visible dilution burden in the provided data, supporting a cleaner capital-allocation profile than many early-stage peers.
The absence of debt-to-equity and compensation detail limits assessment of board discipline and alignment, keeping governance only moderately above average.
No filing-based controversies or control failures are provided, so governance appears stable, but the evidence base is insufficient to justify a stronger peer-relative score.
Overall Score
GTBP’s ESG positioning is broadly neutral to slightly above average versus peers, with limited leverage pressure offset by sparse disclosure across material environmental and social factors.
Score Driver: Limited Disclosure Across Material ESG Dimensions
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on GT Biopharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.